Chiasma

Chiasma

HealthEndocrinology📍 Israel

Chiasma is a biopharmaceutical company focused on developing oral therapies for rare diseases, specifically acromegaly. The company aims to provide a more patient-friendly alternative to existing injectable treatments, which are often painful and inconvenient. Despite recent setbacks, Chiasma is preparing to submit trial results to the FDA and seeks to launch its product in the near future.

Visit website ↗
Total raised
$600M
tracked to date
Latest round
$600M
Sep 1, 2026
Known investors
5
led by F2

Is this your company?

Claim this profile to get matched with investors who fund Health startups in Israel.

Claim this profile →

Funding history

  1. 1
    $600MSep 1, 2026

    Led by F2

    Announcement ↗

Founder

Roni Mamluk
Roni Mamluk
CEO

Investors in Chiasma

Backers from this company's tracked funding rounds.

  • FF2Lead investorVC firm
  • MMPM CapitalVC firm
  • GGE EquityVC firm
  • AAbingworthVC firm
  • AArch Venture PartnersVC firm

Chiasma in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile